While immediate cystectomy offers excellent long-term outcomes for patients with high-grade T1 transitional cell carcinoma, genetic biomarkers one day could help urologists select the most appropriate candidates for this surgery.
Scottsdale, AZ-While immediate cystectomy offers excellent long-term outcomes for patients with high-grade T1 transitional cell carcinoma, genetic biomarkers one day could help urologists select the most appropriate candidates for this surgery. Meanwhile, recent data suggest that optimal bacillus Calmette-Guerin therapy can delay the need for cystectomy without increasing mortality. These insights came from a presentation regarding immediate cystectomy for high-grade bladder cancer at the Perspectives in Urology: Point-Counterpoint meeting held here.
"That finding is true, but the difficulty is that researchers were only looking at the failures," he said. "One can't say that everybody should have up-front cystectomy because those who don't have it fare badly without knowing the denominator: How many do well with bladder-sparing treatments?"
However, he said, such studies are biased against immediate cystectomy because physicians naturally select out the highest-risk cases for this treatment.
"Another problem is that many of the people who say one should do immediate cystectomy are not using the optimal BCG treatment schedule," which includes maintenance BCG, Dr. Lamm added.
Perhaps the strongest argument for maintenance BCG therapy comes from a follow-up of the Southwest Oncology Group 3-week maintenance BCG study that attempted to demonstrate that intravesical therapy and delayed cystectomy worsened survival (J Urol 2007; 177:1727-31).
"In contrast, there was a highly significant-both clinically and statistically-reduction in mortality in patients who actually failed BCG and came to cystectomy," he said. "Those patients did better if they had received 3-week maintenance."
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.